Institute News
Most Popular
Phase 3 Trial Currently Enrolling MacTel Patients
Neurotech Pharmaceuticals, with support from the Lowy Medical Research Institute, is currently enrolling a Phase 3 clinical trial testing ciliary neurotrophic factor (CNTF) in patients with macular telangiectasia type 2. This is a multi-center trial...
Positive Phase 3 Topline Results Announced for NT-501 Implant in MacTel
November 2, 2022 Neurotech Pharmaceuticals, Inc. announces positive Phase 3 topline results for NT-501 implant in macular telangiectaisa type 2 (MacTel). (Cumberland, RI) Clinically relevant and statistically significant primary results with t...
What To Expect in a MacTel Imaging Exam
April 29, 2024 The following information was sent out via email to people who registered in the LMRI Contact Database. This post will explain some (but not all) of the imaging exams that your eye doctor may perform during a screening or follow up...
CNTF Phase 3 Trial Enrollment Complete
September 21, 2020 Neurotech Pharmaceuticals, with support from the Lowy Medical Research Institute, is conducting a Phase 3 clinical trial testing ciliary neurotrophic factor (CNTF) in patients with macular telangiectasia type 2. This is a multi...
Neurotech Receives Priority Review of Biologics License Application for NT-501 as a Treatment for Macular Telangiectasia Type 2
June 20, 2024 LMRI would like to share the news that Neurotech has received Priority Review of Biologics License Application (BLA) for NT-501 (revakinagene taroretcel) as a treatment for MacTel. For more information, please refer to the Neurotech...